SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | n/a |
| Enterprise Value ($M) | n/a |
| Book Value ($M) | 74,353.00 |
| Book Value / Share | 59.55 |
| Price / Book | n/a |
| NCAV ($M) | -21,291.00 |
| NCAV / Share | -17.05 |
| Price / NCAV | n/a |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | 0.06 |
| Return on Assets (ROA) | 0.04 |
| Return on Equity (ROE) | 0.07 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.87 |
| Current Ratio | 1.28 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 30,670.00 |
| Assets | 126,314.00 |
| Liabilities | 51,961.00 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 46,444.00 |
| Operating Income | 10,354.00 |
| Net Income | 5,400.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 10,258.00 |
| Cash from Investing | -6,200.00 |
| Cash from Financing | -8,052.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Amundi | 5.00 | -2.76 | |
| 13G/A | Dodge & Cox | 4.90 | -9.94 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 360,724 | 3,153,956 | 11.44 | |
| 436,575 | 636,263 | 68.62 | |
| 368,994 | 3,714,876 | 9.93 | |
| 237,416 | 1,356,647 | 17.50 | |
| 408,622 | 1,997,215 | 20.46 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ABCL – AbCellera Biologics Inc. | ABOS – Acumen Pharmaceuticals, Inc. |
| ABUS – Arbutus Biopharma Corporation | ACAD – ACADIA Pharmaceuticals Inc. |
| ACLX – Arcellx, Inc. |
Financial data and stock pages provided by
Fintel.io